An open-label extension study to assess long term safety and tolerability of omalizumab treatment in adults and adolescents with severe allergic asthma who participated in the 52 week CIGE250011E2 study.

Next Previous
Trial Profile

An open-label extension study to assess long term safety and tolerability of omalizumab treatment in adults and adolescents with severe allergic asthma who participated in the 52 week CIGE250011E2 study.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions
  • Sponsors Novartis

    • Most Recent Events

    • 25 Nov 2014 Last checked against ClinicalTrials.gov record.
    • 24 Oct 2011 Planned end date changed to 1 Jun 2006 as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.
    • 01 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top